Editorial: Innovative organoid co-culture systems for enhanced precision medicine in cancer and beyond
-
By
-
Talita Glaser
-
Rupert Ecker
-
Uwe Ritter
-
May 27, 2026
Clinical Report: Advancements in Organoid Co-Culture Models for Precision Medicine
Overview
This editorial discusses the emerging role of complex organoid co-culture systems in precision medicine, particularly in oncology. It highlights their utility in therapeutic assessment and treatment response prediction.
Background
Organoid co-culture systems replicate the architecture and interactions found in human tissues, which is crucial for advancing precision medicine. These models facilitate mechanistic studies and the evaluation of therapeutic responses, yet face challenges in clinical translation due to methodological limitations.
Data Highlights
No specific numerical data or trial results were provided in the source material.
Key Findings
- Organoid co-culture systems integrate various biological elements, enhancing the study of disease mechanisms.
- Patient-derived intestinal organoids can model epithelial-specific IFN-I signaling relevant to inflammatory bowel disease.
- A 3D ex vivo platform for colorectal cancer allows functional screening of PD-1 blockade with preserved tissue architecture.
- Osteochondral organoids are emerging as platforms for osteoarthritis research, mimicking cartilage-bone interfaces.
- Clinical translation of organoid models is hindered by methodological and validation challenges.
Clinical Implications
Addressing the existing methodological challenges is essential for the effective clinical application of organoid co-culture models.
Conclusion
Organoid co-culture systems represent a developing area in precision medicine, with ongoing challenges that need to be addressed.
Related Resources & Content
- the pathologist, A Roadmap for Organoid Toxicology, 2026 -- A Roadmap for Organoid Toxicology
- Frontiers in Medicine, Advances and future perspectives of kidney organoid technology in renal disease research and clinical translation, 2026 -- Advances and future perspectives of kidney organoid technology in renal disease research and clinical translation
- the medicine maker, Industrializing Organoids to Bridge the Predictability Gap, 2026 -- Industrializing Organoids to Bridge the Predictability Gap
- Frontiers in Immunology, Editorial: Innovative approaches to immunogenetics and organ transplantation, 2026 -- Innovative approaches to immunogenetics and organ transplantation
- ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice - ScienceDirect, 2025 -- ESMO Precision Oncology Working Group recommendations
- ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial | npj Precision Oncology, 2025 -- ChemoID-guided therapy improves objective response rate
- ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice - ScienceDirect
- ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial | npj Precision Oncology
- Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems - Lab on a Chip (RSC Publishing) DOI:10.1039/D5LC00062A
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
